MRPS16

Across TCGA pan-cancer cohorts, MRPS16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRPS16 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MRPS16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MRPS16 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and HNSC are the cancer types where MRPS16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	1.000	0.433	<.001	21	view →
CCRCC	OS	Median	All	1.000	0.762	.032	2	view →
HNSC	DFS	Median	II,III,IV	0.738	0.565	.034	2	view →
PDAC	DFS	Median	All	0.802	0.646	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRPS16–LSCC (DFS)

Open the LSCC breakdown →